Bavarian Nordic Reports Revenue Growth and Strategic Advances in Q3 2024

Bavarian Nordic A/S reports strong interim financial results for the first nine months of 2024, with total revenue reaching DKK 3,622 million and an 18% increase in its Travel Health division. The company maintains its full-year guidance amidst uncertainties related to mpox vaccine logistics, while securing DKK 2,400 million in vaccine orders for 2025. CEO Paul Chaplin highlights the company’s commitment to global health and its proactive measures in combating the mpox outbreak.